Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Govt committed to supporting pharma companies with industry-friendly policies
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Subscribe To Our Newsletter & Stay Updated
